Dynavax Technologies Corporation (NASDAQ:DVAX) posted its quarterly earnings data on Friday. The biopharmaceutical company reported ($0.38) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.53) by $0.15, Bloomberg Earnings reports. Dynavax Technologies Corporation had a negative net margin of 1,323.99% and a negative return on equity of 92.09%. The company had revenue of $0.05 million during the quarter, compared to the consensus estimate of $0.28 million. During the same quarter in the prior year, the company posted ($0.90) EPS. The company’s quarterly revenue was down 68.8% compared to the same quarter last year.

Dynavax Technologies Corporation (NASDAQ DVAX) traded down $0.20 on Friday, reaching $21.60. 1,396,470 shares of the company were exchanged, compared to its average volume of 1,408,759.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at https://www.watchlistnews.com/dynavax-technologies-corporation-dvax-releases-earnings-results-beats-estimates-by-0-15-eps/1681137.html.

A number of research analysts have recently commented on the stock. Cowen and Company reaffirmed an “outperform” rating and set a $30.00 price objective on shares of Dynavax Technologies Corporation in a research note on Thursday, August 10th. Zacks Investment Research raised shares of Dynavax Technologies Corporation from a “hold” rating to a “buy” rating and set a $11.00 price objective for the company in a research note on Monday, July 10th. BidaskClub downgraded shares of Dynavax Technologies Corporation from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. William Blair reissued an “outperform” rating and set a $30.00 target price on shares of Dynavax Technologies Corporation in a research report on Wednesday, August 9th. Finally, J P Morgan Chase & Co raised shares of Dynavax Technologies Corporation from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $6.00 to $27.00 in a research report on Monday, July 31st. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Dynavax Technologies Corporation currently has a consensus rating of “Buy” and an average price target of $25.00.

Dynavax Technologies Corporation Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Earnings History for Dynavax Technologies Corporation (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.